Search / Trial NCT06236165

Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of Both N-acetylcysteine and Pentoxifylline Supplementation in Patients With Hepatic and Post Hepatic Jaundice

Launched by TANTA UNIVERSITY · Jan 24, 2024

Trial Information

Current as of October 08, 2024

Recruiting

Keywords

Jaundice, N Acetylcysteine, Pentoxifylline

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Patients age 18-70 years old.
  • * Patients diagnosed with jaundice and increased level direct bilirubin ≥ 3 mg/dL.
  • Exclusion Criteria:
  • * Pregnancy.
  • * Nursing mothers.
  • * Patients with increased indirect bilirubin level.
  • * Patients who have Gilbert syndrome or Crigler Najjar syndrome.
  • * Patients with Child Paugh C score (10-15 point).
  • * History of intolerance and hypersensitivity to Pentoxifylline or to xanthine derivatives such as caffeine, theophylline.
  • * Recent hemorrhage.
  • * Patients who have risk factors potentially complicated by hemorrhage.
  • * Taking anticoagulants or antiplatelet therapy.
  • * History of known hypersensitivity to N-acetylcysteine.

About Tanta University

Tanta University is a prestigious academic institution located in Egypt, dedicated to advancing medical research and education. As a clinical trial sponsor, Tanta University leverages its extensive resources and expertise to conduct innovative research initiatives aimed at improving health outcomes. The university collaborates with a network of healthcare professionals, researchers, and institutions to facilitate rigorous clinical trials across various medical disciplines. Committed to ethical standards and scientific integrity, Tanta University strives to contribute to the global body of knowledge while fostering the next generation of medical professionals.

Locations

Tanta, , Egypt

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0